Navigation Links
Rigel Announces Fourth Quarter and Year End 2007 Financial Results
Date:2/12/2008

s of $74.3 million, or $2.57 per share. This compares to revenues of $33.5 million and a net loss of $37.6 million, or $1.51 per share for the same period in 2006. The decrease in revenue is due to various milestone and upfront payments from Merck, Merck Serono and Pfizer recognized in 2006.

As of December 31, 2007, Rigel had cash, cash equivalents and available for sale securities of $108.3 million, compared with $112.5 million at September 30, 2007 and $104.5 million at December 31, 2006. During the first quarter of 2008, we completed a public offering in which we sold 5,000,000 shares of our common stock at a price of $27.00 per share. We received net proceeds of approximately $127.5 million after deducting underwriting discounts and commissions and offering expenses.

"The recent announcement of the results from our Phase 2 clinical trial in rheumatoid arthritis with our lead drug candidate, R788, has focused investors' interest in Rigel's R&D programs," said James M. Gower, Rigel's chairman and chief executive officer. "As a result of our recent financing, we are positioned to move R788 into advanced clinical studies while continuing development of new therapeutic opportunities in our pipeline."

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in seven strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product dev
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rigel to Present at BIO Investor Forum 2007
2. Rigel to Present Research Programs at Scientific Conferences
3. Rigel Announces Pricing of Public Offering of Common Stock
4. Rigel to Present at BIO CEO & Investor Conference
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
(Date:9/2/2015)... ... 02, 2015 , ... Drug companies increasingly are adopting a ... reveals in its new report that the U.S. will generate the greatest demand ... the most market demand. , BCC Research examines plant-derived drugs in its ...
(Date:9/2/2015)... 2015 Aytu BioScience, Inc. (OTCQB: AYTU), a ... and related conditions, announced today that it has closed ... note financing, raising a total of $5.175 million, which ... Josh Disbrow , Chief Executive ... are intended to be used to conduct clinical studies ...
(Date:9/2/2015)... September 2, 2015 BiondVax Pharmaceuticals Ltd. ... National Institute of Allergy and Infectious Diseases (NIAID), part of ... of Health and Human Services (HHS), to launch a new ... United States in the 2015-16 timeframe. The trial ... Multimeric-001 (M-001), as a primer vaccine, which would be administered ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... Veteran journalist Brian Howell, who elevated technology and business ... battle with lung cancer. He was 53. , ... 1997, Howell was features editor and, previously, national-foreign editor ... career also included reporting and editing stints in Montana, ...
... of the first rituals after shaking hands is to take my ... the business world, it is a reflex reaction. In Japan, the ... a few years ago, I had to understand that the proper ... that it actually has a name: meishi (pronounced "may-shee). I learned ...
... Having customers, employees, vendors and partners feel good about ... Laurie Benson, CEO and co-founder of Inacom Information ... solutions reseller. , ,Benson and Inacom were recently recognized ... , for the second year in a row. According ...
Cached Biology Technology:Madison Magazine Editor Dies of Lung Cancer 2Are You Your Business Card? 2Are You Your Business Card? 3Inacoms Benson Receives Top Industry Recognition 2Inacoms Benson Receives Top Industry Recognition 3
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
(Date:8/18/2015)... 18, 2015  Navitas today announced that ... the Submission Content Management webinar scheduled on ... forum. Dedicated to the Implementation of Regulatory Submission ... for industry, vendors, health authorities, consultants and ... towards a standard method of implementing electronic ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... advance that may give brewers powerful new ability to engineer ... alcoholic beverage scientists are publishing the most comprehensive deciphering ... proteome (the set of proteins that make beer "beer") appears ... Pier Giorgio Righetti and colleagues say they were inspired to ...
... a real-life "back to the future" story, scientists today ... to plywood a century ago is re-emerging as a ... at a meeting of the American Chemical Society, they ... substance in soy milk and tofu and could mean ...
... Airport Security Solution -- SUNNYVALE, California, September 29, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology News:HCL Technologies Launches AeroPASS Airport Security Solution 2HCL Technologies Launches AeroPASS Airport Security Solution 3HCL Technologies Launches AeroPASS Airport Security Solution 4HCL Technologies Launches AeroPASS Airport Security Solution 5HCL Technologies Launches AeroPASS Airport Security Solution 6HCL Technologies Launches AeroPASS Airport Security Solution 7HCL Technologies Launches AeroPASS Airport Security Solution 8HCL Technologies Launches AeroPASS Airport Security Solution 9
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
... and Tissue Staining Kits are intended for ... of histological and cytological specimens. These kits ... manufactured by either R&D Systems or by ... the formation of the Avidin-Biotin Complex (ABC) ...
... Cellular uptake of long double stranded ... RNA interference in a diverse group of ... culture. RNA interference leads to the inhibition ... destruction of the target messenger RNA (mRNA). ...
... an easy-to-use siRNA transfection reagent that has ... in a variety of cell lines. jetSI-ENDO ... optimized, straightforward protocol. High levels of gene ... transfection of 20 to 100 nM of ...
Biology Products: